For the Inventor, By the Inventor

Enter assignee name

Thousand Oaks, CA, United States of America

Amgen Inc.

USPTO Granted Patents = 1,971

CIPO Patents = 719

EPO Patents = 627

Trademarks = 150

Forward Citations = 24,351

Loading Chart...

Loading Chart...

3,003 inventors (with patents filed for the assignee):

Ning Chen (55 out of 55 patents)

Thomas Charles Boone (53 out of 54 patents)

Scott Robert Gibson (50 out of 86 patents)

4. Jennifer Rebecca Allen (49 out of 50 patents)

5. Mark Henry Norman (46 out of 51 patents)

6. Jonathan B Houze (45 out of 56 patents)

7. Patricia Lopez (43 out of 43 patents)

8. Andrew Stewart Tasker (43 out of 66 patents)

9. Thomas T Nguyen (40 out of 43 patents)

10. Qingyian Liu (40 out of 40 patents)

11. Julio Cesar Medina (40 out of 73 patents)

12. Chadwick Terence King (39 out of 59 patents)

13. Nobuko Nishimura (39 out of 39 patents)

14. Robert Michael Rzasa (38 out of 38 patents)

15. Shon Booker (37 out of 38 patents)

Core Competencies:

Drug Delivery Devices

Heterocyclic Compounds

KRAS G12C Inhibitors

Antibody Constructs

Metabolic Disorders

Aqueous Antibody Formulation

KIF18A Inhibitors

Autoinjector

Mass Spectrometric Analysis

Closed System Transfer Device

Formulations of Apremilast

Proximity Sensor Technology

1,971 patents: Sort by Forward Citations

1. 12493943 - Apparatuses, systems and methods for plunger-stopper depth measurement in pre-filled syringes (2025-12-09),

2. 12485219 - Drug delivery devices with partial drug delivery member retraction (2025-12-02),

3. 12480858 - Automated visual inspection (2025-11-25),

4. 12473329 - Methods directed to crystalline biomolecules (2025-11-18),

5. 12473289 - Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use (2025-11-18),

6. 12473281 - Synthesis of KRAS G12C inhibitor compound (2025-11-18),

7. 12466825 - Synthesis of KRAS G12C inhibitor compound (2025-11-11),

8. 12465652 - Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins (2025-11-11),

9. D1101191 - Vial sleeve (2025-11-04),

10. 12459932 - KIF18A inhibitors (2025-11-04),

11. 12459896 - Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile (2025-11-04),

12. 12448396 - Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors (2025-10-21),

13. 12448373 - Azetidinyl-acetamides as CXCR7 inhibitors (2025-10-21),

14. 12442027 - Method of reducing aromatic nitro compounds (2025-10-14),

15. 12441796 - Antibody constructs for CDH19 and CD3 (2025-10-14),

Amgen Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines to treat serious illnesses. With a commitment to cutting-edge research and a dedication to improving patient outcomes, Amgen has become a global leader in biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

1,971 Patents

#1 in Thousand Oaks, CA

#59 in California

#247 in US

#495 in the World

Thousand Oaks, CA, United States of America

Amgen Inc.

Forward Citations = 24,351

3,003 inventors:

Ning Chen (55 out of 55 patents)

Thomas Charles Boone (53 out of 54 patents)

Scott Robert Gibson (50 out of 86 patents)

4. Jennifer Rebecca Allen (49 out of 50 patents)

5. Mark Henry Norman (46 out of 51 patents)

Please report any incorrect information to support@idiyas.com

Loading…